FDA 批准第一个治疗多发性硬化的单克隆抗体药物 Tysabri FDA 于 11 月 23 日批准Biogen Idec公司的一项新的生物药物, 用来治疗多发性硬化(MS)复发,以减少疾病的发作次数和防治疾病的恶化。 Tysabri 是那他珠单抗 natalizumab) 的商品名称,它是来自鼠的生物工程单克隆 FDA Approves First Monoclonal Antibody for Multiple Sclerosis Tysabri FDA approved Biogen Idec’s new biopharmaceutical for the treatment of multiple sclerosis (MS) relapse on November 23 to reduce the number of episodes of the disease And prevent the deterioration of the disease. Tysabri is the trade name of natalizumab, which is a bioengineered monoclonal